

HR 1816

Ovarian Cancer Biomarker Research Act of 2009

Congress: 111 (2009–2011, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 31, 2009

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 1, 2009)

Official Text: <https://www.congress.gov/bill/111th-congress/house-bill/1816>

Sponsor

Name: Rep. Berman, Howard L. [D-CA-28]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (35 total)

Cosponsor	Party / State	Role	Date Joined
Del. Bordallo, Madeleine Z. [D-GU-At Large]	D · GU		Mar 31, 2009
Rep. Boucher, Rick [D-VA-9]	D · VA		Mar 31, 2009
Rep. Burton, Dan [R-IN-5]	R · IN		Mar 31, 2009
Rep. Capps, Lois [D-CA-23]	D · CA		Mar 31, 2009
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Mar 31, 2009
Rep. Edwards, Donna F. [D-MD-4]	D · MD		Mar 31, 2009
Rep. Farr, Sam [D-CA-17]	D · CA		Mar 31, 2009
Rep. Green, Gene [D-TX-29]	D · TX		Mar 31, 2009
Rep. Hall, Ralph M. [R-TX-4]	R · TX		Mar 31, 2009
Rep. Hinchey, Maurice D. [D-NY-22]	D · NY		Mar 31, 2009
Rep. Israel, Steve [D-NY-2]	D · NY		Mar 31, 2009
Rep. Kilroy, Mary Jo [D-OH-15]	D · OH		Mar 31, 2009
Rep. King, Peter T. [R-NY-3]	R · NY		Mar 31, 2009
Rep. Lee, Barbara [D-CA-9]	D · CA		Mar 31, 2009
Rep. Maloney, Carolyn B. [D-NY-14]	D · NY		Mar 31, 2009
Rep. McDermott, Jim [D-WA-7]	D · WA		Mar 31, 2009
Rep. McGovern, James P. [D-MA-3]	D · MA		Mar 31, 2009
Rep. McMahon, Michael E. [D-NY-13]	D · NY		Mar 31, 2009
Rep. Serrano, Jose E. [D-NY-16]	D · NY		Mar 31, 2009
Rep. Sestak, Joe [D-PA-7]	D · PA		Mar 31, 2009
Rep. Shea-Porter, Carol [D-NH-1]	D · NH		Mar 31, 2009
Rep. Van Hollen, Chris [D-MD-8]	D · MD		Mar 31, 2009
Rep. Wasserman Schultz, Debbie [D-FL-20]	D · FL		Mar 31, 2009
Rep. Wolf, Frank R. [R-VA-10]	R · VA		Mar 31, 2009
Rep. Kucinich, Dennis J. [D-OH-10]	D · OH		May 5, 2009
Rep. McHugh, John M. [R-NY-23]	R · NY		May 13, 2009
Rep. Nadler, Jerrold [D-NY-8]	D · NY		May 14, 2009
Rep. Clarke, Yvette D. [D-NY-11]	D · NY		Jun 26, 2009
Rep. Kirk, Mark Steven [R-IL-10]	R · IL		Jul 7, 2009
Rep. Davis, Danny K. [D-IL-7]	D · IL		Sep 8, 2009
Rep. Slaughter, Louise McIntosh [D-NY-28]	D · NY		Oct 21, 2009
Rep. Moore, Dennis [D-KS-3]	D · KS		Nov 3, 2009
Rep. Sutton, Betty [D-OH-13]	D · OH		Jan 20, 2010
Rep. Walz, Timothy J. [D-MN-1]	D · MN		Jul 15, 2010
Rep. Emerson, Jo Ann [R-MO-8]	R · MO		Nov 15, 2010

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 1, 2009

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
111 S 755	Related bill	Mar 31, 2009: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Mar 31, 2009)

Ovarian Cancer Biomarker Research Act of 2009 - Amends the Public Health Service Act to require the Director of the National Cancer Institute to enter into cooperative agreements with, or make grants to, public or nonprofit entities to establish and operate Ovarian Cancer Biomarker Centers of Excellence to conduct research on biomarkers for use in risk stratification for, and the early detection and screening of, ovarian cancer, focusing on translational research of such biomarkers. Permits federal funds to be used for research on: (1) the development and characterization of new biomarkers and the refinement of existing biomarkers; (2) the clinical and laboratory validation of such biomarkers; (3) the development and implementation of clinical and epidemiological research on the utilization of such biomarkers; (4) the development and implementation of repositories for new tissue, urine, serum, and other biological specimens; and (5) genetics, proteomics, and pathways of ovarian cancer as they relate to the discovery and development of biomarkers.

Requires the Director to: (1) make available for research banked serum and tissue specimens from clinical research regarding ovarian cancer that was funded by the Department of Health and Human Services (HHS); and (2) establish an Ovarian Cancer Biomarker Clinical Trial Committee to assist in designing and implementing national clinical trials to determine the utility of using such biomarkers.

Requires a national data center to be established in, and supported by, the Institute to conduct statistical analyses of trial data and to store such analyses and data, which shall be used to establish clinical guidelines to provide the medical community with information regarding the use of validated biomarkers.

Actions Timeline

- **Apr 1, 2009:** Referred to the Subcommittee on Health.
- **Mar 31, 2009:** Introduced in House
- **Mar 31, 2009:** Referred to the House Committee on Energy and Commerce.